Companies-in-Residence

Accelerating the development of new therapies

The companies currently hosted within Fogarty Innovation span a wide range of sectors and technologies. However they are all united by a common goal—improving patient care.

Chronus Health

While many of our vital signs are easily obtained, the one test that doctors rely on to make the majority of their diagnoses—the blood test—can take hours, if not days, for results. Chronus Health has developed a portable device that provides lab results in minutes, allowing for real-time diagnosis and thus promising to dramatically improve time-to-care and patient outcomes. The startup has focused its initial efforts on complete blood count (CBC) and comprehensive metabolic panel (CMP), which account for 50 percent of all blood tests performed in the United States.

Enspectra Health

Skin cancer is the most common form of malignancy, with more individuals diagnosed each year than for all other cancers combined. For the last 150 years these malignancies have required an invasive biopsy for diagnosis, but Enspectra is leading a digital transformation in pathology by imaging real-time cellular anatomy in living tissue, without cuts or stains.

G-Tech Medical

Up to 60 million individuals in the U.S. suffer from debilitating gastrointestinal disorders. G-Tech Medical is developing a wearable technology aimed at improving outcomes and reducing costs by non-invasively monitoring gastrointestinal tract activity.

Healyx Labs

More than 110 million people worldwide suffer from non-healing, open wounds. High costs and overly complex technology severely limit, if not eliminate, access to advanced wound care technology. Healyx Labs is developing the lowest-cost and easiest-to-use wound vacuum technology for price-sensitive and underserved markets.

iDentical

One hundred seventy-eight million adults in the United States are missing at least one tooth, and a surprising 40 million are missing all their teeth. Currently, dental implants are the top choice of treatment, yet less than two percent of those impacted by tooth loss are able to reap the benefits due to limited accessibility, high cost, high risk and long treatment time. iDentical is leveraging the latest 3D technology to offer a safer, faster and more affordable solution through its drill-free, non-invasive dental implants.

Materna Medical

Approximately 50 percent of all women in the U.S. will suffer symptoms of a pelvic floor disorder resulting from childbirth by the time they turn 55, and over 20 million suffer from pelvic pain. Materna has developed an obstetrics and gynecology (OB-GYN) platform of medical devices: the first, Prep, is aimed at preventing maternal pelvic injuries during childbirth and shortening delivery time; the second, Milli, is helping treat pelvic pain and dyspareunia.

Nasus Medical

More than 36 million patients in the U.S. suffer from chronic rhinosinusitis. In fact, the condition accounts for 1 to 2% of all physician visits and is associated with $7 to 12 billion in direct U.S. healthcare costs per year. Nasal steroid sprays are typically prescribed as standard of care, but are only partially effective as they cannot reach beyond the anterior portion of the nasal cavity. Maximal medical therapy (sprays and pills) fail in 50% of patients, leaving them with the options of taking repetitive systemic drugs with serious side effects, having expensive, invasive procedures or continuing to suffer without sufficient treatment. Nasus Medical is developing solutions for improved intra-nasal drug delivery through an innovative technology that is designed for patients to treat themselves at home, early in the pathway.

palmm

Fifteen million Americans suffer from hyperhidrosis, also known as excessive sweating. This condition can dramatically affect quality of life in both social and professional settings. palmm is developing a simple, at-home treatment for hyperhidrosis, initially focusing on the hands.

Voyant

Urine sample collection remains a standard method used to determine the proper course of treatment for patients and to prevent exposure to potentially harmful medications and procedures. Voyant is automating the urinary diagnostics process with its innovative smart toilet platform, reducing the collection and testing time from about one hour to just five minutes.